KALY Cannabis Pharma News Lights Up PPS Ready To Run From $0.01 to $0.04 On Way To $0.10

New York, NY -- April 3, 2019 -- InvestorsHub NewsWire -- www.nextbigticker.com -- Kali-Extracts, Inc. (USOTC: KALY) revealed yesterday for the first time ongoing patented cannabis extract Type 2 Diabetes Treatment research the company had previously kept under wraps adding to the recently published research results from the company’s pilot Chronic Obstructive Pulmonary Disease (COPD) treatment evaluation. The press release yesterday indicated two more cannabis extract health issue treatments are also soon to be revealed. KALY trading has shot to the OTC top 25 most actively traded list with the PPS edging toward a breakout. The PPS is above the 200 Day MA and has now broken past the 50 Day MA following a MACD cross. The candlestick analysis is indicating VERY BULLISH.

“The market is finally giving hints of a bullish resurgence. Today a bullish pattern is detected. “
AmericanBulls.com

KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10

KALY has the potential to run from its $0.01 PPS level to $0.10 in the near term. Shortly after the 2018 Q4 acquisition of the patented cannabis extraction process, the company PPS shot from sub-penny land to almost $0.04 on volume that put it in the top 20 most actively traded stocks on the OTC Market. The PPS retraced back to $0.01 and has been holding that price with a healthy trading volume. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is a reasonable milestone following the company filing its upcoming annual reported expected to include the company posting its first revenue derived from its cannabis extraction process. The company filed an extension on the 2018 annual report with the report itself now expected within the next 15 days.

KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acred hemp farm.

Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.

Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com